Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/125923
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury
Author: Robertson, S.A.
Hutchinson, M.R.
Rice, K.C.
Chin, P.-Y.
Moldenhauer, L.M.
Stark, M.J.
Olson, D.M.
Keelan, J.A.
Citation: Clinical and Translational Immunology, 2020; 9(4):e1121-1-e1121-19
Publisher: Wiley
Issue Date: 2020
ISSN: 2050-0068
2050-0068
Statement of
Responsibility: 
Sarah A Robertson, Mark R Hutchinson, Kenner C Rice, Peck-Yin Chin, Lachlan M Moldenhauer, Michael J Stark, David M Olson, Jeffrey A Keelan
Abstract: Every year, 15 million pregnancies end prematurely, resulting in more than 1 million infant deaths and long-term health consequences for many children. The physiological processes of labour and birth involve essential roles for immune cells and pro-inflammatory cytokines in gestational tissues. There is compelling evidence that the mechanisms underlying spontaneous preterm birth are initiated when a premature and excessive inflammatory response is triggered by infection or other causes. Exposure to pro-inflammatory mediators is emerging as a major factor in the 'fetal inflammatory response syndrome' that often accompanies preterm birth, where unscheduled effects in fetal tissues interfere with normal development and predispose to neonatal morbidity. Toll-like receptors (TLRs) are critical upstream gatekeepers of inflammatory activation. TLR4 is prominently involved through its ability to sense and integrate signals from a range of microbial and endogenous triggers to provoke and perpetuate inflammation. Preclinical studies have identified TLR4 as an attractive pharmacological target to promote uterine quiescence and protect the fetus from inflammatory injury. Novel small-molecule inhibitors of TLR4 signalling, specifically the non-opioid receptor antagonists (+)-naloxone and (+)-naltrexone, are proving highly effective in animal models for preventing preterm birth induced by bacterial mimetic LPS, heat-killed Escherichia coli, or the TLR4-dependent pro-inflammatory lipid, platelet-activating factor (PAF). Here, we summarise the rationale for targeting TLR4 as a master regulator of inflammation in fetal and gestational tissues, and the potential utility of TLR4 antagonists as candidates for preventative and therapeutic application in preterm delivery and fetal inflammatory injury.
Keywords: Fetal inflammatory injury; inflammation; pregnancy; preterm; TLR4 antagonist; Toll-like receptor 4
Rights: © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1002/cti2.1121
Grant ID: http://purl.org/au-research/grants/nhmrc/1140916
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_125923.pdfPublished version3.63 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.